‘Multipronged Approach’ Necessary for Mitigating Opioid Disparities in CancerFebruary 12th 2023
An expert from Dana-Farber Cancer Institute says that policymakers and insurers should take a hard look at policies that restrict opioid use in patients with cancer who are at end of life, especially for underserved communities.
Expert Seeks to Assess Opioid Access Disparities in Younger Cancer PopulationFebruary 11th 2023
After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.
ODAC Votes 8-5 in Favor of Dostarlimab Trial in Advanced Rectal CancerFebruary 9th 2023
In a meeting with the FDA’s Oncologic Drugs Advisory Committee experts discussed findings that have read out with regard to dostarlimab for patients with mismatch repair deficiency/microsatellite instability–high locally advanced rectal cancer.
Bendamustine/Rituximab Appears Tolerable in Geriatric Mantle Cell LymphomaFebruary 9th 2023
Real-world findings from an observational study indicate that bendamustine plus rituximab appears to be well tolerated by elderly patients with transplant-ineligible mantle cell lymphoma and indolent non-Hodgkin lymphoma.
SBRT Provides Positive Locoregional Control in Lung Neuroendocrine TumorsFebruary 9th 2023
Data from a retrospective study suggests that stereotactic body radiotherapy may be a suitable alternative to surgical resection for patients with primary lung neuroendocrine tumors, according to an expert from Moffitt Cancer Center.
Expert Highlights Gender/Racial Disparities in Opioid Access for Cancer Near End of LifeFebruary 9th 2023
An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.
ctDNA Detection May Predict Neoadjuvant Immunotherapy Response in MIBCFebruary 8th 2023
Investigators identify an association between circulating tumor DNA in the blood plasma detected via the RaDaR assay and response to treatment with neoadjuvant immunotherapy for muscle-invasive bladder cancer.
Atezolizumab Plus Bevacizumab Shows Potential in TMB-H Nonsquamous NSCLCFebruary 7th 2023
Findings from the phase 2 TELMA trial suggest that atezolizumab plus bevacizumab yields robust, long-lasting outcomes for patients with metastatic nonsquamous tumor mutational burden–high non–small cell lung cancer.
Favorable Outcomes Associated With Early MRD Following Allo-SCT in AMLFebruary 6th 2023
Findings from a study indicate that measurable residual disease clearance is associated with favorable outcomes in acute myeloid leukemia following subsequent therapy before allogenic stem cell transplant.
From Clinical Trials to Real-World Practice, Experts Examine the Best Options for TNBCFebruary 4th 2023
During a live Tweet Chat, Hope S. Rugo, MD, and Paolo Tarantino, MD, reviewed a patient case and discussed current standard of care for those with metastatic triple-negative breast cancer.
Survey Highlights Need for Mental Health Support Throughout Cancer ContinuumFebruary 3rd 2023
Lack of access to adequate mental health care affects both patients and survivors of cancer who experience significant burdens, highlighting a need for normalization, according to a licensed clinical social worker.